Anglichan: Subsidiary passes drug GMP compliance inspection.

Angli Kang announced that its holding subsidiary, Hunan Kuirui Biopharmaceutical Co., Ltd., has received the "Drug GMP Compliance Inspection Notice" issued by the Hunan Provincial Drug Administration. The inspection scope includes the finasteride active pharmaceutical ingredient production line, and the inspection time is from April 23 to April 25, 2025, with the conclusion that it meets the requirements. Through the GMP compliance inspection, Kuirui Biopharmaceuticals finasteride active pharmaceutical ingredient production line has met the GMP requirements, and its products can be marketed. This will help improve the company's product structure, enrich the variety of products, enhance the company's industry influence and competitiveness, and have positive significance for the company to meet market demand and achieve stable development in the future.